Insider Selling: CSL Limited (ASX:CSL) Insider Sells 4,000 Shares of Stock

CSL Limited (ASX:CSL) insider Paul McKenzie sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, October 31st. The shares were sold at an average price of A$287.15 ($190.17), for a total value of A$1,148,600.00 ($760,662.25).

Paul McKenzie also recently made the following trade(s):

• On Tuesday, September 3rd, Paul McKenzie acquired 8,275 shares of CSL stock. The stock was purchased at an average cost of A$306.03 ($202.67) per share, with a total value of A$2,532,398.25 ($1,677,084.93).

CSL Price Performance

The company has a debt-to-equity ratio of 62.80, a current ratio of 2.17 and a quick ratio of 1.68.

CSL Increases Dividend

The business also recently disclosed a Final dividend, which was paid on Tuesday, October 1st. Investors of record on Tuesday, October 1st were paid a dividend of $2.203 per share. The ex-dividend date of this dividend was Sunday, September 8th. This represents a dividend yield of 0.73%. This is a positive change from CSL’s previous Final dividend of $1.99. CSL’s dividend payout ratio (DPR) is presently 50.38%.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.